Results 41 to 50 of about 187,871 (305)

Neutralization of the boost vaccines by mice immune sera after the prime vaccination.

, 2021
Mouse immune sera against VSV-SARS-CoV-2 msp-SF-Gtc were prepared by vaccinating interferon α and β receptor knock out mice (Ifnar-/- mice, Jackson Laboratory, B6.129S2-Ifnar1tm1Agt/Mmjax) once with 5X108 PFU of rVSVInd-msp-SF-Gtc.
Taewoo Kim (1456888), Ryan M. Troyer (11846435), Sun-Je Woo (10336425), Eric J. Arts (11846438), Kunyu Wu (11846408), S. M. Mansour Haeryfar (8069414), Jung-ah Choi (6520727), Seungho Choo (11846423), Gregory A. Dekaban (9694262), Brock Fenton (359975), Gyoung Nyoun Kim (11846405), Gippeum Lim (7253675), Na Hyung Kim (1315179), Nasrin Saeedian (11846411), Kate Parham (11846429), Jae-Hyung Chang (327325), Andrew Winterborn (11846426), Hoe Won Jeong (11846420), Eunsil Choi (8271039), Justin M. Donovan (11846432), Su-Kyeong Eo (11846417), Jimmy D. Dikeakos (8871386), Manki Song (317984), Yue Li (102191), Hayan Park (9182877), Eunji Yang (9182871), Seong-Gyu Kim (11846414), C. Yong Kang (11846444), Sangkyun Lee (312151), Sang Hwan Seo (10838327), Stephen D. Barr (11846441)   +30 more
core   +1 more source

Protective antiviral immune responses to pseudorabies virus induced by DNA vaccination using dimethyldioctadecylammonium bromide as an adjuvant

, 2002
To enhance the efficacy of a DNA vaccine against pseudorabies virus (PRV), we evaluated the adjuvant properties of plasmids coding for gamma interferon or interleukin-12, of CpG immunostimulatory motifs, and of the conventional adjuvants ...
Eddie G. te Lintelo, te Lintelo, E.G., Wim J. A. Boersma, Rooij, E.M.A., van, Yolanda E. de Visser, Boersma, WJA, Lintelo, E.G., te, Boersma, W.J.A., Visser, Y.E., de, Hilgers, LAT, Haagmans, Bart, van Rooij, EMA, Bart L. Haagmans, Bianchi, ATJ, Harrie L. Glansbeek, Hilgers, L.A.T., Haagmans, B.L., Glansbeek, H.L., Andre T. J. Bianchi, van Rooij, E.M.A., Glansbeek, HL, Eugene M. A. van Rooij, de Visser, Y.E., Luuk A. T. Hilgers, Bianchi, A.T.J., Lintelo, EG, de Visser, YE   +26 more
core   +1 more source

«FREE» AND «BOUND» ANTIBODIES AGAINST HIV–1 STRUCTURE PROTEINS AT EARLY STAGE OF THE DISEASE

Медицинская иммунология, 2014
. Using ELISA and immunoblotting we have monitored the activity of “free” antibodies against virus structure proteins in the sera of HIV–infected patients at the stage of the developing humoral immune response. Further, a comparative assessment of “free”
G. A. Rjazanova, V. P. Kocksin, R. V. Khamzina   +2 more
doaj   +1 more source

The Antigenicity of Epidemic SARS-CoV-2 Variants in the United Kingdom

Frontiers in Immunology, 2021
To determine whether the neutralization activity of monoclonal antibodies, convalescent sera and vaccine-elicited sera was affected by the top five epidemic SARS-CoV-2 variants in the UK, including D614G+L18F+A222V, D614G+A222V, D614G+S477N, VOC-202012 ...
Jiajing Wu, Jiajing Wu, Li Zhang, Yue Zhang, Yue Zhang, Haixin Wang, Haixin Wang, Ruxia Ding, Jianhui Nie, Qianqian Li, Qianqian Li, Shuo Liu, Yongxin Yu, Yongxin Yu, Xiaoming Yang, Kai Duan, Kai Duan, Xiaowang Qu, Youchun Wang, Weijin Huang   +19 more
doaj   +1 more source

Neutralizing activity of WNV-immune sera.

, 2017
Sensitivity of WNV WT and T198F RVPs to neutralization by 2-mercaptoethanol (2-ME)-treated or untreated (unt) sera pooled from WT-immune (n = 5) (A and C) or T198F-immune (n = 5) (B and D) five-week old WT C57BL/6J mice. Sera were obtained at 6 (A and B)
Michael S. Diamond (106070), Kimberly A. Dowd (129927), Leslie Goo (3752755), Theodore C. Pierson (129937), Laura A. VanBlargan (493223)   +4 more
core   +1 more source

Immunological genomics of Brugia malayi:filarial genes implicated in immune evasion and protective immunity [PDF]

, 2001
Filarial nematodes are metazoan parasites with genome sizes of> 100 million base pairs, probably encoding 15 000-20 000 genes. Within this considerable gene complement, it seems likely that filariae have evolved a spectrum of immune evasion products ...
Scott, Alan, Scott, A L, Maizels, Rick, Blaxter, Mark   +3 more
core   +1 more source

Emapalumab for Immune Effector Cell‐Associated Hemophagocytic Lymphohistiocytosis‐Like Syndrome Following CD19‐Directed CAR‐T in Two Patients With B‐ALL: Clinical and Biomarker Correlates

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Immune effector cell‐associated hemophagocytic lymphohistiocytosis‐like syndrome (IEC‐HS) is a life‐threatening hyperinflammatory toxicity distinct from cytokine release syndrome (CRS) and neurotoxicity following chimeric antigen receptor T‐cell (CAR‐T) therapy. In a single‐institution retrospective cohort of pediatric and young adult patients
Thomas J. Galletta, Jeremy D. Rubinstein, Christopher E. Dandoy, Ruby Khoury, Angela Faulhaber, Christine L. Phillips, Christa Krupski   +6 more
wiley   +1 more source

The Role of Hematopoietic Cell Transplantation in Ataxia‐Telangiectasia

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Ataxia‐telangiectasia (A‐T) is a DNA repair disorder characterized by neurodegeneration, immunodeficiency, and cancer predisposition. Hematopoietic cell transplantation (HCT) is an established therapy in related disorders such as Fanconi anemia (FA) and Nijmegen breakage syndrome (NBS), but its role in A‐T is unclear.
Laila Alkhouli, Seth Rotz, Masatoshi Takagi, Richa Sharma   +3 more
wiley   +1 more source

Human Anti-Als3p Antibodies Are Surrogate Markers of NDV-3A Vaccine Efficacy Against Recurrent Vulvovaginal Candidiasis

Frontiers in Immunology, 2018
A Phase 1b/2a clinical trial of NDV-3A vaccine containing a Candida albicans recombinant Als3 protein formulated with alum protected women <40 years old from recurrent vulvovaginal candidiasis (RVVC).
Priya Uppuluri, Priya Uppuluri, Shakti Singh, Abdullah Alqarihi, Clint S. Schmidt, John P. Hennessey, Michael R. Yeaman, Michael R. Yeaman, Scott G. Filler, Scott G. Filler, John E. Edwards, John E. Edwards, Ashraf S. Ibrahim, Ashraf S. Ibrahim   +13 more
doaj   +1 more source

Neutralization of Different Variants of SARS-CoV-2 by a F(ab′)2 Preparation from Sera of Horses Immunized with the Viral Receptor Binding Domain

Antibodies, 2023
The Receptor Binding Domain (RBD) of SARS-CoV-2, the virus responsible for the COVID-19 pandemic, is the functional region of the viral Spike protein (S), which is involved in cell attachment to target cells.
Mariajosé Rodriguez-Nuñez, Mariana del Valle Cepeda, Carlos Bello, Miguel Angel Lopez, Yoneira Sulbaran, Carmen Luisa Loureiro, Ferdinando Liprandi, Rossana Celeste Jaspe, Flor Helene Pujol, Héctor Rafael Rangel   +9 more
doaj   +1 more source